Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-RAGE in Healthy Subjects and Asthma Patients
NCT05276570Phase 2Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Jun 2022
- Primary completion
- Apr 2025
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 5
01
Overview
A Phase 2 trial of ARO-RAGE in asthma, sponsored by Arrowhead Pharmaceuticals. Started Jun 2022; status: completed.
02
Drugs
ARO-RAGE
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05276570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05276570.